ISOMEDIX REPORTS RECORD SECOND QUARTER RESULTS
ISOMEDIX REPORTS RECORD SECOND QUARTER RESULTS WHIPPANY, N.J., July 21 /PRNewswire/ -- Isomedix Inc.
(NASDAQ: ISMX) today reported a 25 percent increase in second quarter consolidated sales to $9,380,946 when compared with sales of $7,511,344 for the same period in 1991. Operating income increased 16 percent to $2,836,927 compared with $2,438,140 for the same period last year.
Consolidated net income in the second quarter increased 32 percent to $2,022,495, compared with $1,531,817 earned a year ago. Based on 7,109,557 weighted average number of common shares outstanding in the second quarter compared with 7,040,942 shares a year ago, earnings per share were 28 cents for the second quarter compared with 22 cents for the same period last year, up 27 percent. Consolidated sales for the six months ended June 30, 1992, increased 26 percent to $17,858,858 compared with $14,136,473. Operating income increased 20 percent to $5,279,157 compared with $4,386,896 for the same period last year. Consolidated net income for the six months ended June 30, 1992, increased 26 percent to $3,542,199 compared with $2,810,619 earned a year ago. Based on 7,120,958 weighted average number of common shares outstanding in 1992 compared with 6,976,506 shares a year ago, earnings per share were 50 cents compared with 40 cents for the same period last year, up 25 percent. John Masefield, chairman and CEO of Isomedix, stated, "We are pleased to report increased sales in both gamma and ethylene oxide sterilization services for the quarter. The gamma sector continued its strong growth and ethylene oxide sales increased, in part, as a result of commissioning of additional chambers in El Paso and South Carolina." The company operates a network of nine sterilization facilities in seven states and Canada and construction is under way on a 10th facility in New York state, expected to open in early 1994. The capability to sterilize medical devices with pure ethylene oxide has been added at two of the gamma facilities and is currently being added to a third facility. Isomedix also provides validation services through its Skyland Scientific Services subsidiary located in Montana. ISOMEDIX INC. (Unaudited) Periods ended Three months Six months June 30: 1992 1991 1992 1991 Sales $9,380,946 $7,511,344 $17,858,858 $14,136,473 Operating income 2,836,927 2,438,140 5,279,157 4,386,896 Net income 2,022,495 1,531,817 3,542,199 2,810,619 Earnings per share $.28 $.22 $.50 $.40 Weighted average number of shares outstanding 7,109,557 7,040,942 7,120,958 6,976,506 -0- 7/21/92 /CONTACT: Thomas J. DeAngelo, vice president-finance and administration of Isomedix, 201-887-4700/ (ISMX) CO: Isomedix Inc. ST: New Jersey IN: MTC SU: ERN
CK-TS -- NY051 -- 1274 07/21/92 11:16 EDT
|Printer friendly Cite/link Email Feedback|
|Date:||Jul 21, 1992|
|Previous Article:||FIRST NATIONAL BANK CORP. POSTS INCREASED SECOND-QUARTER RESULTS|
|Next Article:||EARLE PALMER BROWN & SPIRO WINS NATIONAL ADDY AWARD FOR UNITED WAY PUBLIC SERVICE AD|